No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
ciltacabtagene autoleucel Sensitive: A1 - Approval
J&J Press Release - 2 days (NewA1)
|
ciltacabtagene autoleucel Sensitive: A1 - Approval
J&J Press Release - 2 days - (New A1)
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
selinexor Sensitive: A1 - Approval
Karyopharm Press Release - 1 week (NewA1)
|
selinexor Sensitive: A1 - Approval
Karyopharm Press Release - 1 week - (New B)
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
Chr amplification(1)(q21)
|
Multiple Myeloma
|
Chr amplification(1)(q21)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
Chr t(14;16)
|
Multiple Myeloma
|
Chr t(14;16)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
MAGEC1 expression
|
Multiple Myeloma
|
MAGEC1 expression
|
Multiple Myeloma
|
bortezomib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
bortezomib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
miR-16 underexpression
|
Multiple Myeloma
|
miR-16 underexpression
|
Multiple Myeloma
|
RD Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
RD Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
MCT1 overexpression + SLC16A3 overexpression
|
Multiple Myeloma
|
MCT1 overexpression + SLC16A3 overexpression
|
Multiple Myeloma
|
metformin + syrosingopine Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
metformin + syrosingopine Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide + elotuzumab Sensitive: A1 - Approval
|
pomalidomide + elotuzumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
carfilzomib Sensitive: A1 - Approval
|
carfilzomib Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib + panobinostat Sensitive: A1 - Approval
|
bortezomib + panobinostat Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
SVd Sensitive: A1 - Approval
|
SVd Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide Sensitive: A1 - Approval
|
pomalidomide Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
thalidomide Sensitive: A1 - Approval
|
thalidomide Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
isatuximab-irfc Sensitive: A1 - Approval
|
isatuximab-irfc Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
prednisone + thalidomide + melphalan Sensitive: A1 - Approval
|
prednisone + thalidomide + melphalan Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
lenalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval
|
lenalidomide + daratumumab / hyaluronidase Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
lenalidomide + elotuzumab Sensitive: A1 - Approval
|
lenalidomide + elotuzumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
lenalidomide + daratumumab Sensitive: A1 - Approval
|
lenalidomide + daratumumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
lenalidomide + ixazomib Sensitive: A1 - Approval
|
lenalidomide + ixazomib Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
daratumumab/hyaluronidase Sensitive: A1 - Approval
|
daratumumab / hyaluronidase Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib Sensitive: A1 - Approval
|
bortezomib Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
lenalidomide Sensitive: A1 - Approval
|
lenalidomide Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
VTD Sensitive: A1 - Approval
|
VTD Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
belantamab mafodotin Sensitive: A1 - Approval
|
belantamab mafodotin Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
denosumab Sensitive: A1 - Approval
|
denosumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
melphalan flufenamide Sensitive: A1 - Approval
|
melphalan flufenamide Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide + isatuximab-irfc Sensitive: A1 - Approval
|
pomalidomide + isatuximab-irfc Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
lenalidomide + carfilzomib Sensitive: A1 - Approval
|
lenalidomide + carfilzomib Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
daratumumab + pomalidomide Sensitive: A1 - Approval
|
daratumumab + pomalidomide Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
daratumumab Sensitive: A1 - Approval
|
daratumumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
isatuximab-irfc Sensitive: A1 - Approval
|
isatuximab-irfc Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
idecabtagene vicleucel Sensitive: A1 - Approval
|
idecabtagene vicleucel Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
zoledronic acid Sensitive: A1 - Approval
|
zoledronic acid Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
daratumumab + thalidomide Sensitive: A1 - Approval
|
daratumumab + thalidomide Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
thalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval
|
thalidomide + daratumumab / hyaluronidase Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide + daratumumab/hyaluronidase Sensitive: A1 - Approval
|
pomalidomide + daratumumab / hyaluronidase Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
dexamethasone tablets Sensitive: A1 - Approval
|
dexamethasone tablets Sensitive: A1 - Approval
|
Chr t(11;14)
|
Multiple Myeloma
|
Chr t(11;14)
|
Multiple Myeloma
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
lenalidomide + bortezomib Sensitive: A2 - Guideline
|
lenalidomide + bortezomib Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib + elotuzumab Sensitive: A2 - Guideline
|
bortezomib + elotuzumab Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
D-VTd Sensitive: A2 - Guideline
|
D-VTd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
ixazomib Sensitive: A2 - Guideline
|
ixazomib Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
RD Sensitive: A2 - Guideline
|
RD Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
VMP Sensitive: A2 - Guideline
|
VMP Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
VRD Sensitive: A2 - Guideline
|
VRD Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bendamustine Sensitive: A2 - Guideline
|
bendamustine Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
melphalan Sensitive: A2 - Guideline
|
melphalan Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
venetoclax + dexamethasone Sensitive: A2 - Guideline
|
venetoclax + dexamethasone Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
cyclophosphamide Sensitive: A2 - Guideline
|
cyclophosphamide Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
panobinostat Sensitive: A2 - Guideline
|
panobinostat Sensitive: A2 - Guideline
|
Chr del(17)(p13)
|
Multiple Myeloma
|
Chr del(17)(p13)
|
Multiple Myeloma
|
bortezomib Sensitive: A2 - Guideline
|
bortezomib Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
PVD Sensitive: A2 - Guideline
|
PVD Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
EloRd Sensitive: A2 - Guideline
|
EloRd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
IRd Sensitive: A2 - Guideline
|
IRd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
KRd Sensitive: A2 - Guideline
|
KRd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
DRd Sensitive: A2 - Guideline
|
DRd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
DVMP Sensitive: A2 - Guideline
|
DVMP Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
CyBorD Sensitive: A2 - Guideline
|
CyBorD Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
EloPd Sensitive: A2 - Guideline
|
EloPd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
Isa-PD Sensitive: A2 - Guideline
|
Isa-PD Sensitive: A2 - Guideline
|
Chr t(11;14)
|
Multiple Myeloma
|
Chr t(11;14)
|
Multiple Myeloma
|
VenVd Sensitive: A2 - Guideline
|
VenVd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
DVD Sensitive: A2 - Guideline
|
DVD Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
IsaKd Sensitive: A2 - Guideline
|
IsaKd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
DKd Sensitive: A2 - Guideline
|
DKd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
DCEP Sensitive: A2 - Guideline
|
DCEP Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
selinexor + pomalidomide Sensitive: A2 - Guideline
|
selinexor + pomalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
selinexor + daratumumab Sensitive: A2 - Guideline
|
selinexor + daratumumab Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
BVD Sensitive: A2 - Guideline
|
BVD Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
BRD Sensitive: A2 - Guideline
|
BRD Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
ixazomib + pomalidomide Sensitive: A2 - Guideline
|
ixazomib + pomalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide Sensitive: A2 - Guideline
|
pomalidomide Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
D-KRd Sensitive: A2 - Guideline
|
D-KRd Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
selinexor + carfilzomib Sensitive: A2 - Guideline
|
selinexor + carfilzomib Sensitive: A2 - Guideline
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
galinpepimut-S Sensitive: B - Late Trials
|
galinpepimut-S Sensitive: B - Late Trials
|
Chr amplification(1q)
|
Multiple Myeloma
|
Chr amplification(1q)
|
Multiple Myeloma
|
VRD Resistant: B - Late Trials
|
VRD Resistant: B - Late Trials
|
Chr t(11;14)
|
Multiple Myeloma
|
Chr t(11;14)
|
Multiple Myeloma
|
venetoclax + bortezomib Sensitive: B - Late Trials
|
venetoclax + bortezomib Sensitive: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
bortezomib + selinexor Sensitive: B - Late Trials
|
bortezomib + selinexor Sensitive: B - Late Trials
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
KD Sensitive: B - Late Trials
|
KD Sensitive: B - Late Trials
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
VD Sensitive: B - Late Trials
|
VD Sensitive: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
DVD Sensitive: B - Late Trials
|
DVD Sensitive: B - Late Trials
|
Chr t(14;16)
|
Multiple Myeloma
|
Chr t(14;16)
|
Multiple Myeloma
|
DVD Sensitive: B - Late Trials
|
DVD Sensitive: B - Late Trials
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
DVD Sensitive: B - Late Trials
|
DVD Sensitive: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + elotuzumab Sensitive: B - Late Trials
|
lenalidomide + elotuzumab Sensitive: B - Late Trials
|
CD38 expression
|
Multiple Myeloma
|
CD38 expression
|
Multiple Myeloma
|
daratumumab Sensitive: B - Late Trials
|
daratumumab Sensitive: B - Late Trials
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
venetoclax + bortezomib + dexamethasone Sensitive: B - Late Trials
|
venetoclax + bortezomib + dexamethasone Sensitive: B - Late Trials
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
daratumumab Sensitive: B - Late Trials
|
daratumumab Sensitive: B - Late Trials
|
Chr t(14;16)
|
Multiple Myeloma
|
Chr t(14;16)
|
Multiple Myeloma
|
daratumumab Sensitive: B - Late Trials
|
daratumumab Sensitive: B - Late Trials
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
daratumumab Sensitive: B - Late Trials
|
daratumumab Sensitive: B - Late Trials
|
BCL2 overexpression
|
Multiple Myeloma
|
BCL2 overexpression
|
Multiple Myeloma
|
venetoclax Sensitive: B - Late Trials
|
venetoclax Sensitive: B - Late Trials
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
PBCAR269A Sensitive: B - Late Trials
|
PBCAR269A Sensitive: B - Late Trials
|
TNFRSF17 expression
|
Multiple Myeloma
|
TNFRSF17 expression
|
Multiple Myeloma
|
belantamab mafodotin Sensitive: B - Late Trials
|
belantamab mafodotin Sensitive: B - Late Trials
|
RPL5 expression
|
Multiple Myeloma
|
RPL5 expression
|
Multiple Myeloma
|
bortezomib Sensitive: B - Late Trials
|
bortezomib Sensitive: B - Late Trials
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
selinexor Sensitive: B - Late Trials
|
selinexor Sensitive: B - Late Trials
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
ALLO-715 Sensitive: B - Late Trials
|
ALLO-715 Sensitive: B - Late Trials
|
Chr t(11;14)
|
Multiple Myeloma
|
Chr t(11;14)
|
Multiple Myeloma
|
TD Resistant: B - Late Trials
|
TD Resistant: B - Late Trials
|
Chr t(11;14)
|
Multiple Myeloma
|
Chr t(11;14)
|
Multiple Myeloma
|
VTD Resistant: B - Late Trials
|
VTD Resistant: B - Late Trials
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
JNJ-64007957 Sensitive: B - Late Trials
|
JNJ-64007957 Sensitive: B - Late Trials
|
Chr amplification(1)(q21)
|
Multiple Myeloma
|
Chr amplification(1)(q21)
|
Multiple Myeloma
|
pomalidomide + isatuximab-irfc Sensitive: B - Late Trials
|
pomalidomide + isatuximab-irfc Sensitive: B - Late Trials
|